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I. ORAL ADMINISTRATION OF SULFAPYRIDINE: ANALYSIS OF 301 CASES
L. J. A. LOEWENTHAL, M.D., M.R.C.P., D.T.M. & H.
Although considerable advances have been made in the understanding and management
of eczematous eruptions, there remains the need for a non-specific remedy with an effect
comparable to that of the anti-histaminics in urticaria. This series of papers is submitted
in the hope that drugs may be found for the alleviation and suppression of symptoms in
eczema and atopic dermatitis; such a discovery would not take the place of rational investi-
gation and treatment any more than does the use of anti-histaminics in cases of urticaria.
These have, of course, been tried extensively in eczema, first on the assumption that what is
"anti-allergic" must also be "anti-eczematous", and later because they were found to
exert an anti-pruritic effect in some patients. Thus Baer and Sulzberger (1) first had prom-
ising results in a small series of cases of atopic and eczematous dermatitis; soon, however,
Sulzberger (2) was to remark that he had found the anti-histaminic drugs not at all effective
in eczematous contact dermatitis and only slightly beneficial in reducing itching in isolated
and few cases of atopic dermatitis. Later Bettley and Spence (3) obtained rather better
results, using Anthisan and Antistin, more recently synthesized antihistaminic drugs: 13
of 22 cases showed subjective or objective improvement, and 10 showed both. Encouraging
as these figures are, they do not approach the success obtained in similar treatment of
urticaria.
The use of sulfapyridine followed on the observation that it was beneficial in most cases
of dermatitis herpetiformis (Swartz & Lever, 4). Gordon and Loewenthal (5), believing
that many cases of chronic eczema were variants of this disease, obtained satisfactory
results in suppressing symptoms and signs with the use of sulfapyridine. The next step was
the realization that the clinical and histologic pictures of such cases of "endogenous ec-
zema" differed in no way from those of cases of auto-sensitization or of the generalized
eczematous states which may follow contact dermatitis. Such cases can, in fact, be diff-
erentiated only by careful history-taking and, occasionally patch-testing. In these cases,
too, sulfapyridine appeared to alleviate signs and symptoms.t Finally, the drug was tried
in other forms of eczema and in atopic dermatitis, and the results prompted me to com-
municate with Messrs. May & Baker, in the hope that some other closely related substance
could be found, which would prove superior to sulfapyridine. The preliminary results
which I mentioned have apparently gained recognition and one may find in a recent pub-
lication (6) that sulfapyridine "has been used successfully in cases of eczema and other
sensitization skin reactions."
EXPERIMENTAL
The average daily dose of sulfapyridine was 3 tablets (1.5 grams), propor-
tionately reduced for children. A few severe cases were given 3 or 4 grams daily
for a short time and the dose reduced as improvement occurred. In some instances
3 tablets daily could not be tolerated, but 2 could be taken. If there was sufficient
improvement the dose was normally reduced from 3 to 2 tablets daily at the end
of a week, and then to 1 tablet at the end of the second week. There were naturally
* This compound title has been chosen in order to include those conditions, such as
atopic dermatitis, which cannot strictly be classified as eczemas.
f The drug was obviously not used when sensitization to sulfonamides was suspected.
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slight deviations from this plan in some cases, but the figures given above repre-
sent both the average and the mode of variations. The great majority of patients
were ambulant during treatment; a few were advised to rest for the first few
days.
Side effects were remarkably rare. 2 cases of drug eruption, one of them an
acquired light-sensitivity, were encountered. Both cleared promptly when sul-
fapyridine was withheld About 25% of patients complained of depression, head-
ache, nausea or vomiting; in all but 3 a temporary reduction of dosage enabled
them to continue until their progress justified taking only 1 tablet on retiring.
This dose is usually well tolerated. Leukocyte counts were done in many patients
during the early stage of this investigation; persistent absence of significant
changes then persuaded me that this precaution was not necessary as a routine.
The large number of infants and children in this series was singularly free from
any of the disagreeable side effects observed in adults.
Many patients had previous sulfonamide medication for minor ailments such
as coryza, sore throat and influenza; the small number of untoward effects sug-
gests that the population has not become sensitized to an appreciable extent.
When arsenic was given in addition to sulfapyridine it was either as 3 minims
(0.2 c.c.) of Fowler's solution or as a 3* grain (0.25 gram) tablet of carbarsone
3 times daily. Prolonged courses were never given in view of the dangers of late
sequelae, and the average period of administration was 2 weeks; arsenic was not
usually repeated in the treatment of relapses. Anti-histaminics were not given.
Local treatment was kept to a minimum. Potentially harmful applications were
discontinued in the few cases who confessed to using them; in many others the
application of bland substances such as calamine lotion was allowed to continue.
Where a placebo was indicated a shake lotion containing 3% of Burow's solu-
tion or 1% of liquor picis carbonis was prescribed. It is not my belief that such
applications alone could have produced more than transient and incomplete
relief. When there was secondary infection, or when an eczematous eruption had
its origin from an infected cutaneous focus, such as impetigo, local treatment of
the infected areas was given in addition to sulfapyridine medication. Vioform was
the usual remedy as 2% or 3% in a shake lotion or cream.
Classification of Cases
No classification of eczema-dermatitis can please everyone, and in a series of
this size there must be cases assigned to incorrect groups. Thus, an unreliable
history or unwillingness to cooperate in investigation may result in examples of
eczematous contact dermatitis being overlooked and classified with endogenous
eczema. Again, certain group distinctions are almost impossible to delimit:
should all cases of infantile eczema be regarded as manifestations of atopy?
If so, must they be grouped with adults who have suffered from atopic dermatitis
since infancy? Should these again be combined with flexural dermatitis appear-
ing for the first time in adults? In order to evade rather than answer these and
similar questions I have placed the cases in categories which are at least homo-
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geneous; the relationships of the various Categories are ignored, but they have
been arranged so as to bring related groups together.
Results *
The results are those of partial or Complete suppression of symptoms and signs
over a period of from 1 month to 4 years. A skin which has once reacted by mani-
festing eczema or dermatitis must always be under suspicion of reacting again
when adverse conditions, specific or non-specific, are encountered. Many pa-
tients who have had a complete remission communicate from time to time, per-
sonally or through their physician, to say that they remain well; others have been
lost sight of. Still others have repeated attacks which they themeselves control
with sulfapyridine; these have been designated as "Relapse/Response". A fair
number belong to certain medical benefit organizations, thus ensuring that they
would have to be seen personally by me in the event of a relapse.
"Improvement" is here taken to mean an appreciable degree of symptomatic
relief along with objective improvement. In chronic cases such relief is considered
significant only when it exceeds the temporary spontaneous improvements that
are often experienced.
Maintenance doses have been required in many cases, as they are in dermatitis
herpetiformis, and recrudescences often have to be checked by temporarily in-
creasing the dose. Patients whose dermatoses have recurred over many years are
to be regarded as improved if a given attack is controlled more quickly with treat-
ment, and in some instances when further attacks are prevented by maintenance
doses of sulfapyridine.
The tables represent 301 consecutive cases who took sulfapyridine and reported
back at least once. They were attended in private practice, and include many
seen and treated by Dr. S. Gordon. 297 were whites, 2 Indian and 2 Chinese.
The sexes are represented about equally. Results in a further series of cases,
treated at the Johannesburg General Hospital over the same period, are com-
parable; their records are, however, difficult of access and hence are not included.
Gioup I—Infantile Eczema.
These cases manifested the disease in the first year of life. The majority began
with a rash of the face and milk crust and after a varying interval developed
eczematous lesions of the trunk and/or limbs; this agrees closely with Hall's (7)
findings. Such cases are often called "dermatitis seborrheica of infants" and are
suggestive of a primary impetigo with secondary bacterid or auto-sensitization
(Gordon, 8). Hence local treatment to the scalp and face was usually instituted
at the same time as sulfapyridine therapy.
Comment: Most of these cases have been followed for periods varying from 1
month to 1 years and 11 remain well. In some infants the original (? impetigi-
* (i) The cases in this series have been indexed separately, and records are available for
scrutiny.
(ii) The figure "693" is used throughout the tables in place of "sulfapyridine".
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nous) area remained troublesome for a few weeks after the generalized eruption
cleared, and eventually responded to local treatment.
Group Il—Atopic Dermatitis (Besnier's Prurigo, Flexural Eczema).
The patients in this group showed their first manifestation in early childhood,
27 of them before the age of 2 years. The eldest (No. 257) had the disease con-
tinuously for 27 years, since early infancy.
Comment: 7 patients remain symptom-free more than a year later, 3 of them
on small maintenance doses of sulfapyridine. Duration of the disease appeared
to make no difference to the speed of initial response, though the presence of
pronounced lichenification entailed a longer course of treatment, and delay in
TABLE I
Infantile eczema
DRUG
693
693 + arsenic
NUMBER
OF CASES
16
3
AVERAGE
AGE AT
ONSET IN
WEEKS
13
5
AVERAGE
DURATION OF
DISEASE IN
WEEKS
43
171
IMPROVED IN WEEKS
1 2 5
6 8 2
1* 2 —
RELAPSE!
RESPONSE
3
FAILED
—
1
Total 19 11.7 63 7 10 2 3 1
* This child subsequently had a relapse which could not be satisfactorily controlled with
further medication.
TABLE II
Atopic dermatitis
DRUG NUMBER OFCASES
AVERAGE
OURATION OP
DISEASE IN
YEARS
IMPROVED IN WEEKS
RELAPSE!
RESPONSE FAILED
1 2 3
693
693 + arsenic
18
10
4.5
12.8
4
4
9
1
5
1
3
3
—
4
Total 28 7.5 8 10 6 6 4
reducing the dosage. In 2 cases there had been previous, temporary response to
arsenic.
Group 111—Chronic Disseminated Neurodermatitis (Atopic Dermatitis).
This group is distinguished from the previous one only by the age of onset being
at or after puberty. It is not suggested that the etiology of these cases is neces-
sarily different from that of Group II, and it will be seen that the results of treat-
ment are comparable.
Comment: The greater proportion of those given arsenic as well as sulfapyridine,
as compared with Group II, is due to the fact that this group consisted of adults
exclusively. Again the course of arsenic was a short one, and it was not given a
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second time; hence responses after relapse took place while the patients were on
sulfapyridine only.
Group I V—A cute Endogenous Eczema.
These cases were of a duration of less than 2 months before treatment was
begun. Origin from contact dermatitis or auto-sensitization had been excluded
as far as possible by the history and clinical appearances. One of the patients
developed the eczematous eruption 2 days after an injection of procaine-peni-
cillin; it had proved unresponsive to various anti-histaminic drugs.
Comment: The high incidence of improvement in the first week should no doubt
be correlated with the fact that the disease had been evident for less than 2
TABLE III
Chronic dis8eminated neurodermatitis
DRUG
693
693 + arsenic
NUMBER OP
CASES
7
17
AVERAGE
DURATION OF
DISEASE IN
YEARS
2.4
7.3
IMPROVED IN WEEKS
RELAPSE!
RESPONSE
—
4
FAILED
1
4
1
5
5
2
1
5
3
—
2
4
—
1
Total 24 6.0 10 6 2 1 4 5
TABLE IV
Acute endogenous eczema
DRUG NUMBER OPCASES
IMPROVED IN WEEKS
RELAPSE!
RESPONSE RAILED
1 2 3 4
693
693 + arsenic
24
23
19
20
4
—
—
1
1
—
2
1
—
2
Total 47 39 4 1 1 3 2
months. Actually those who improved in the first week averaged a previous dura-
tion of only 2.7 weeks' illness, the others 3.9 weeks.
Group V—Chronic Endogenous Eczema.
The remarks preceding Table IV are applicable here, except that the duration
of the disease was more than 2 months in every case. Several had recurrent at-
tacks over many years, and in those whose attacks were normally short the fig-
ures given in Table V will naturally give an unfair bias in favour of the results
of therapy. Nevertheless, improvement was noted for record only when the pa-
tient stated that treatment had reduced the normal duration of the attack.
Comments: (1). 24 of this series, including some of those designated Relapse/
Response, are on continuous maintenance doses of 1 to 3 tablets (0.5 to 1.5
grams) of sulfapyridine daily. Some of them also feature in the series described
by Gordon and Loewenthal (5).
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(2). 8 patients showed improvement on sulfapyridine oniy, after showing no
response to 2 weeks' arsenic therapy.
(3). The series includes 3 patients whose eczematous eruptions were located on
sun-exposed areas. However, the margins always extended on to unexposed areas;
thus in men who wore open-neck shirts the rash on the chest was U-shaped, not
V-shaped. These patients became almost well in the first 2 weeks and had no
residual sun-sensitivity, even while on sulfapyridine treatment.
(4). 4 patients were given daily doses of 6 tablets (3 grams) of sulfapyridine
because of the severity of their condition (Nos. 1, 142, 170, 219). Only one was
given arsenic in addition. All showed considerable improvement in the first
week.
TABLE V
Chronic endogenous eczema
DRUG NUMBER OFCASES
IMPROVED IN WREES
RELAPSE!
RESPONSE
5
8
FAILED
4
4
1
20
37
I
2 3 4 5
12 2 1 —
12 2 3 1
693
693 + arsenic
39
59
Total 98 57 24 4 4 1 13 8
TABLE VI
Five patients, who would otherwise be classified as endogenous eczema, had
their eruption oniy since becoming pregnant. They are listed separately here.
Comment: (1). Arsenic was not given to these patients.
(2). At least one patient has required maintenance doses of sulfapyridine
since her pregnancy terminated.
Group Vil—Nummular Eczema.
This ill-defined group is based purely on clinical grounds. The disease is
presumably a manifestation of a number of causes, differing between cases, and
inability to incriminate dietary, bacterial or other factors does not necessarily
absolve them from suspicion in these cases. But as this is an attempt to assess
the value of sulfapyridine in cases of eczema and atopic dermatitis, irrespective
of their etiology, these cases are presented as a group without apology.
Pregnancy cases
Group VI—Pregnancy Cases.
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Comment: 3 cases responded to sulfapyridine only, having previously re-
sponded to arsenic. 2 responded to sulfapyridine who had previously been given
arsenic without benefit.
Group Vill—Residual Eczema after Contact Dermatitis.
This type of case commonly follows over-treatment, and many patients listed
here originally developed local eczema from the application of acrifiavine to
minor injuries of the skin. Subsequently a generalized eczematous outbreak
occurred, with exacerbation on re-exposure to acrifiavine. Where patch-testing
is considered safe the result is constantly positive. A similar train of events can
follow sensitization to any other contact allergen—cosmetics, wood dusts and so
TABLE VII
Nummular eczema
DRUG
693
693 + arsenic
NUMBER OF
CASES
14
6
DURATION IN
YEARS
9.0
4.3
IMPROVED IN WEEKS
RELAPSE!
RESPONSE
3
—
FAILED
2
2
1
7
3
2
5
—
3
—
—
4
—
1
Total 20 6.5 10 5 — 1 3 4
TABLE VIII
Residual eczema after eczematous contact dermatitis
DRUG NUMER OFCASES
IMPROVED IN WEEKS
RELAPSE!
RESPONSE FAILED
1 2
693
693 + arsenic
19
21
14
9
3
8
3
3
2
4
Total 40 23 11 6 6
on. This group comprises those whose eczema was caused this way, but who
continue to exhibit its manifestations even when not exposed to the allergen.
Pirilä and Kilpio (9) have recently drawn attention to instances of residual
dermatitis after bichromate rashes persisting up to a year after ceasing contact
with the allergen.
Comment: "Duration" is not tabulated as it was found impossible in many
cases to distinguish the residual eczema period from the period of exposure to the
allergen.
Group IX—Auto-sensitization Eczema.
It will be recalled that one of the clinical varieties of auto-sensitization origi-
nally described by Whitfield (10) consisted of widely-distributed papulo-vesicular
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patches occurring after an exacerbation of chronic lichenified eczema. The clinical
picture is well known to dermatologists; it need not follow exclusively on chronic
eczema. Engman (11) has stated that it occurs in about one fourth of the cases
in which there is an acute dermatitis in some part of the body—and it is treated
as distinct from the general sensitivity developing after contact dermatitis
(Group VIII). Cormia (12) has made important investigations which suggest
that the antigen in these cases is a water-soluble fraction of epidermal cells.
Comment: The figures do not necessarily reflect improvement in the original
lesion, merely in the secondary eczematous eruption.
TABLE IX
Auto-sensitization eczema
DRUG NUMBER ORCASES
7
9
DURATION
months
42
11.7
IMPROVED IN WEEKS
RELAPSE!
RESPONSE
1
3
1
6
5
2
—
3
3
1
1
693
693 + arsenic
Total 16 25 11 3 2 4
TABLE X
Infectious eczematoid dermatitis
DRUG NUMBER OPCASES
DURATION IN
REARS
IMPROVED IN WEEKS
RAILED
1 2
693
693 + arsenic
3
1
0.8
2.5
2
—
—
—
1
1
Total 4 1.25 2 — 2
Group X—Infectious Eczematoid Dermatitis.
This is taken to mean an eczematous reaction in an area contaminated with
infectious discharges, e.g. around persistent axillary boils, or the pinna in a case
of chronic discharging otitis media.
Statistical Note
No significant difference is found in responses in Groups I to X. The figures
suggest that improvement takes place more quickly in cases where the disease
is of recent origin, and this is in accordance with expectation, for diseases of
short duration should provide a greater proportion of spontaneous recoveries.
Table XI shows that while improvement took place equally in the first week,
whether sulfapyridine was given alone or with arsenic, in the second week
sulfapyridine alone produced more improvements. Testing these figures with the
Loewenthal-Wilson (13) table, we find that the observed difference (46 against
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32) is statistically significant at P = .05. This means that the odds are 19 to 1
against such a difference occurring by chance. A similar significance attaches to
the higher rate of failures on sulfapyridine + arsenic, in the last column. The
rational explanation is that the sulfapyridine + arsenic "population" tends to
include the more chronic and serious cases, to whom one would naturally give
the more intensive treatment.
Patch Tests
Serial patch-tests were done in 5 cases of contact dermatitis with generalized
sensitization, i.e. an eczematous eruption appearing spontaneously on parts not
in contact with the allergen. The sites of application were on unaffected areas of
skin.
No. 33. White male, age 61, carpenter. Has had recurrent attacks of an itching
rash on face, neck and forearms for 10 years. Noticed that working with Imbuya
wood produced attacks. Present attack 1 month. Is still working with Imbuya.
V2 Jan. 1950. Severe vesicular, squamous and partly lichenified eczema affecting
TABLE XI
Data provided by summation of tables I—X
DRUG
693
693 + arsenic
NUMEEE OF
CASES
152
149
IMPROVED IN WEEKS
RELAPSE!
RESPONSE FAILED
10 mci.
21 mcI.
1
86
84
2
44
31
3
8
7
4
2
5
5
2
1
22
20
Total 301 170
(57%)
75
(25%)
15
(5%)
7
(2%)
3
(1%)
42
(14%)
31
(10%)
face, neck, hands and forearms. Taken off work. Given sulfapyridine, 1 tablet
(0.5 gram) thrice daily. Lead-in-milk lotion. Progress as below:
Imbuys pate/i-test
Date At war/i Eczema (24 hours) 693
12 Jan. Stops ++ ++ begun
26Jan. off
2Feb. off
3 Feb. Resumes work stops
8 Feb. working + ++
13 Feb. working
20 Feb. working +
24 Feb. working + neg +
This patient subsequently had 2 relapses, took sulfapyridine irregularly, and by
August was clear. Since May he had not worked with Imbuya wood.
No. 56. White female, age 43. Housewife. 5 years' recurrent summer eruption
where metal articles are in contact with the skin. This summer also in ante-
cubital fossae, where there is no metal contact.
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Patch-tests
Date Eczema Nickel Chrome Adhesive tape 693
23 Nov. ++ ++ begun
2ODec. -
In this case there was no recurrence of the generalized eczema but contact with
metal invariably produced a local reaction, whether she was taking sulfapyridine
or not.
No. 171. White male, age 48. Office executive. Recurring, almost constant
rash of hands and feet from age of 6 until 44, when contact dermatitis from
leather discovered. Remained wel], when not in contact with leather, except for
areas of papular eczema on back of neck and shoulders, where no contact with
leather occurred. Temporary or no benefit from local applications and from roent-
gen therapy. Patch-tests with leather (not chrome) always positive since first
done in 1945.
Dale Eczema Leather patch-test, 48hours 693
2 Nov. + ++ begun
23Nov.
This patient had no recurrence in a year and has taken no more sulfapyridine.
Unwilling to have more patch-tests.
No. 182. White female, age 51. Housewife. Eczema in area of shoe and garter
contact for 6 months. Recently affecting parts not in contact with leather.
Date Eczema Leather patch-test, 48 hours 693
2 Dec. +± + begun
22 Dec. neg +
Patient lost sight of and presumed well, as she had understood instructions about
wearing canvas shoes.
Discussion
(i). Action of Sulfonamides in various dermatoses: The reason for the selection
of sulfapyridine has been discussed. When several sulfonamides are active in
varying degrees in apparently non-bacterial dermatoses, it is usually found that
sulfapyridine is the most effective. Thus, in discussing the treatment of dermatitis
herpetiformis, Lever (14) placed sulfapyridine first, sulfathiazole second, sul-
fanilamide third and sulfadiazine a poor fourth. Similarly Sulzberger (15) gave
sulfapyridine as the drug of choice in dermatitis herpetiformis, acrodermatitis
continua, dermatitis repens, impetigo herpetiformis and relapsing, non-sup-
purative, nodular panniculitis. He stressed the point that the drug must be given
for a long time, a dictum which applies also to many of the cases under review
here. Careful study of the literature, and especially of society meetings, shows
that these views have been generally adopted. Nevertheless, earlier reports show
that sulfonamides other than sulfapyridine have been credited with clearing up
eczematous eruptions. Combes and Canizares (16), for instance, quote Sutton
and Sutton as obtaining good results in "eczema of the legs" from the use of
sulfanilamide. and Cornbleet similarly in "chronic exudative dermatitis with
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edema of the ears." Lindsay (17) also claimed to have cleared up a case of chronic
eczema of 10 years' standing with small doses of sulfanilamide, and Shoch (18)
is reported as observing improvement with sulfanilamide in nummular eczema.
Larger doses were recommended by Fox (19) for the same condition. Both
Andrews (20) and Costello (21) have seen good results from sulfapyridine in the
Sulzberger-Garbe disease.
It is generally accepted that the foregoing results were not due to any anti-
bacterial action on the part of the drug employed. In the first place the dosage
customarily used is too small to raise the sulfonamide blood-level to the necessay
concentration. Secondly it has been shown, at least in dermatitis herpetiformis,
that the beneficial action of sulfapyridine is not inhibited by giving para-amino-
benzoic acid simultaneously, as would undoubtedly be the case if an anti-bacterial
action were required (Kiaber & Yorke (22); Feisher (23)).
(ii). Role of arsenic: The results, including a consideration of cases responsive
to either or both drugs, show that either sulfapyridine or arsenic can produce
improvement in some eczema or dermatitis patients, but the former drug appeared
to act more constantly. There is no apparent advantage in combining the two.
(iii). It cannot be over-emphasized that the results are to be viewed in terms
of suppression, partial or complete. If the disease does not recur when suppressive
therapy is stopped it may simply mean that the skin, having been sufficiently
rested, loses its altered capacity to react. This is a vague concept, but one that
has a parallel in some cases of urticaria on suppressive treatment with anti-
histaminics. It may also be that the psychological effect of suppressing a chronic
and disfiguring eruption may be enough to neutralize anxiety in cases of neuro-
dermatitis.
(iv). The 5 cases in whom patch-test studies were made are of some interest.
Nilzén (24) used the same approach with antihistaminics. He found no change
in positive patch-test results when anti-histaminics were given orally before and
during the period of patch-testing. With the cases on sulfapyridine therapy, on
the other hand, there was a tendency for patch-tests to be less positive or even
negative under these conditions. In the single case (No. 33) in whom sulfapyridine
was mixed with the allergen, the patch-test became more positive. This result
agrees with Nilzén's, using a mixture of nickel and antihistaminic. While the
general specific epidermal sensitivity was reduced there was no such change in
areas previously reacting to contact. Thus, Case No. 33 showed a local flare-up
to his allergen on parts affected with eczema, even when his patch-test had
become negative.
(v). Caution should be exercised in accepting the numerical results (Table XI)
too trustingly. They refer only to improvement, usually in the first few weeks of
treatment, and there are undoubtedly many cases who have been lost sight of
and in whom the condition has relapsed, to be unresponsive to further sulfa-
pyridine therapy. On the other hand, the immediate results are often so impres-
sive as to gain the patient's confidence and lighten the task of investigation and
treatment. Many physicians are now using this treatment without reference to
a dermatologist, and it has become routine practice in the Chamber of Mines
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Hospital, Johannesburg. This is not necessarily a good thing, for there are real
dangers in the indiscriminate use of sulfapyridine, even in small doses. On the
other hand other sulfonamides are constantly used in self-medication of minor
ailments, and in much larger doses. The effects in this series have not been
serious, but this does not dispose of the element of risk.
Summary and Conclusions
1. 301 cases of eczema or atopic dermatitis were treated with small doses of
sulfapyridine. 149 of these were also given small doses of arsenic by mouth.
2. 83% showed subjective and objective improvement in the first 2 weeks.
3. The series has been subdivided to compare the response to sulfapyridine
with and without arsenic.
4. Further subdivision shows results in clinically different groups of cases.
5. No serious side effects from sulfapyridine were observed in this series.
6. In 5 cases of eczematous contact dermatitis on sulfapyridine, the behavior
of reactions to patch-tests was observed. These tended to become less positive
while the patient was on sulfapyridine.
7. Results indicate that sulfapyridine may suppress symptoms and signs in
many cases. It is, in the writer's experience, the most successful non-specific
agent in treating eczema and atopic dermatitis.
8. The indiscriminate use of sulfapyridine for this purpose is not advised, but
its action may help in directing research to the discovery of related compounds
which are less toxic and more effective. Since this paper was written sodium
para-aminobenzoate has given satisfactory results in a few trials.
REFERENCES
1. BARR, R. L. AND SULZBEROER, M. 13. Pyribenzamine in the treatment of itching skin
conditions. J. Invest. Dermat. 7: 147.
2. SULZBERGER, M. B. (In discussion). Ibid. 8:77.
3. BETTLEY, F. R. AND SPENCE, M. P. The therapeutic Action of Pyranisamine maleate
and 2- phenylbenzylaniinomethyl-imidazoline Acta Dermato-Vener. 49: 266, 1949.
4. SWARTZ, J. H. AND LEVEE, W. F. Dermatitis herpetiformis: immunologic and thera-
peutic considerations. Arch. Dermat. & Syph. 47: 680, 1943.
5. Goarorc, S. AND LOEWENTRAL, L. J. A. Chronic eczema as a variant of dermatitis
herpetiformis. Brit. J. Dermat. & Syph. 61: 359, 1949.
6. MAY AND BAKER, Ltd. Medical Diary, p. 43, 1951.
7. HALL, A. J. An inquiry into the aetiology of infantile eczema. Brit. J. Dermat. & Syph.
17: 287 (1905).
8. GORDON, S. Personal communication.
9. PIRILA, V. AND KILPIb, 0. On dermatoses caused by bichromates. Acts Dermato-Vener.
29: 550, 1949.
10. WIJITFIELD, A. The question of sensitiveness to non-bacterial toxins and proteins.
Brit. J. Dermat. & Syph. 34: 331, 1922.
11. ENOMAN, M. F. In discussion. Arch. Dermat. & Syph. 61: 944, 1950.
12. CORMIA, F. E. Auto-eczematization: Preliminary Report. Ibid. 931, 1950.
13. LOEWENTHAL, L. J. A. AND WILsoN, W. A. Problems of chance in medicine and research.
Brjt. Med. J. ii: 110, 1939.
14. LEVER, W. F. In discussion. Arch. Derinat. & Syph. 49: 362, 1944.
15. SULZBERGER, M. B. Year Book of Dermatology. p. 10, 1946.
CHEMOTHERAPY OF ECZEMA—DERMATITIS 399
16. C0MBES, F. C. AND CANIZARES, 0. Sulfanilamide and allied compounds. Arch. Dermat.
& Syph. 44: 236, 1941.
17. LINDSAY, H. C. L. In discussion. Ibid. 47: 609, 1943.
18. Sriocn, A. J. Chemotherapy. 15: 36, 1938. Quoted in previous discussion.
19. Fox, E. C. In discussion. Arch. Dermat. & Syph. 41: 1074, 1941.
20. ANDRJIWS, G. C. In discussion, Ibid. 59: 359, 1949.
21. COSTELLO, M. J. In discussion. Ibid.
22. KLABER, R. AND YORKE, S. J. Roy. Inst. Pub. Health & Hyg. 7: 8, 1944. Quoted in
Hawking, F. and Lawrence, J. S. The Sulphonamides, London. H. K. Lewis & Co.
p. 246.
23. FELSHER, Z. In discussion. Arch. Dermat. & Syph. 60: 889, 1949.
24. NILZN, A. The action of histamine antagonists on the histamine wheal and the eczema
test (Patch-Test). Acta Dermato-Vener. 30: 1, 1950.
